XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B | 8-K: FY2025 Q3 Revenue: USD 9.351 M

LB filings
2025.11.12 12:48
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 9.351 M.

EPS: As of FY2025 Q3, the actual value is USD 0.7.

Segment Revenue

  • XOMA Royalty received $43.9 million in royalties and milestones from its partners in the first nine months of 2025, including $14.3 million from royalties during the third quarter.

Operational Metrics

  • Income and revenue for the three and nine months ended September 30, 2025, were $9.4 million and $38.4 million, respectively, compared to $7.2 million and $19.8 million for the corresponding periods of 2024.
  • R&D expenses for the three and nine months ended September 30, 2025, were $69 thousand and $1.4 million, respectively, compared with $0.8 million and $2.0 million for the corresponding periods of 2024.
  • G&A expenses for the three and nine months ended September 30, 2025, were $9.7 million and $25.7 million, respectively, compared to $8.0 million and $27.5 million for the corresponding periods of 2024.
  • Net income for the three and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding periods of 2024.

Cash Flow

  • Net cash provided by operating activities was $8.4 million for the nine months ended September 30, 2025, compared to - $10.8 million for the same period in 2024.
  • Cash, cash equivalents, and restricted cash at the end of the period were $130.6 million as of September 30, 2025.

Unique Metrics

  • Gains on acquisitions in the third quarter of 2025 were $17.9 million for HilleVax and $1.8 million for Turnstone.

Outlook / Guidance

  • XOMA Royalty anticipates several clinical readouts over the coming months and quarters that, if positive, can meaningfully shape its business trajectory. The company aims to become a self-sustaining entity from royalties alone over the near term. Forward-looking statements include potential commercial payments and developments related to various assets in XOMA Royalty’s portfolio.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.